Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria - results the APPRECIATE study

• Main Authors: Constanze Jonak (Author), Isolde Göttfried (Author), Sylvia Perl-Convalexius (Author), Barbara Gruber (Author), Martina Schütz-Bergmayr (Author), Igor Vujic (Author), Wolfgang Weger (Author), Nikolaus Schicher (Author), Lydia Semlin (Author), Margit Hemetsberger (Author), Myriam Cordey (Author), Paul Sator (Author)
• Format: Book
• Published: SAGE Publishing, 2023-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Apremilast, an oral phosphodiesterase 4 inhibitor, is approved in the European Union for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients refractory or contraindicated to or intolerant of other systemic therapies. Objectives: The APPRECIATE study assessed ap...